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Introduction and background
===========================

Infective endocarditis (IE) has long been recognized and treated over three centuries starting from 1674 when Lazare Riviere first noticed IE as a disease \[[@REF1]\]. The overall annual incidence of IE varies from 3 to 7 per 100,000 person-years in the global population study while Bor et al. reported that approximately 40,000 IE cases/year with a 14.5% mortality rate occurred in the USA \[[@REF2],[@REF3]\]. IE can be caused by various pathogens including bacteria and fungus although the former is more common. Due to frequent invasive procedures such as cardiac catheterization, defibrillator and central line placement, Staphylococcus aureus has become the most causal organism followed by Streptococcus species with an estimated incidence of 49.3% and 24.7%, respectively \[[@REF2]\].

Coagulase-negative Staphylococci (CoNS) is known to be a nonpathogenic commensal in individuals with normal immune response. However, this concept changed when Staphylococcus lugdunensis, a member of the CoNS group, was first identified as a causal pathogen of IE in 1988 by Freney et al. \[[@REF4]\]. Although most CoNS tend to have more latent pathogenicity, S. lugdunensis is an exception with a higher degree of virulence similar to Staphylococcus aureus. S. lugdunensis often requires immediate and aggressive treatment including surgical intervention. Embolic complications related to IE represent a more severe endpoint of the disease including S. lugdunensis endocarditis-induced embolic stroke. The question regarding how and when to start treatment remains unclear as no definitive management plan is described in the guidelines.

This review article aims to evaluate the clinical presentation, characteristics and risk factors, as well as the necessity of surgical treatment in cerebrovascular accident (CVA) due to S. lugdunensis endocarditis.

Review
======

Materials and methods

We performed an extensive literature search using Pubmed, Medline, Scopus, and Google Scholar to identify peer-reviewed original research, review articles, case reports and series using 'Staphylococcus lugdunensis', 'infective endocarditis', 'stroke', and 'cerebrovascular accident'. The search period included all the articles published until January 2017. Search result yielded mostly case reports and case series. Patient characteristics, risk factors, echocardiographic findings, vegetation size, required surgical intervention and its complications, and mortality rate were reviewed in detail (Figure [1](#FIG1){ref-type="fig"}).
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Results

A total of 17 original published articles were considered appropriate for inclusion in our review article (Figure [1](#FIG1){ref-type="fig"}). Out of these 17 studies, 16 were case reports from Italy \[[@REF5],[@REF6]\], Switzerland \[[@REF7]\], USA \[[@REF8]-[@REF11]\], UK \[[@REF12],[@REF13]\], Morocco \[[@REF14]\], Taiwan \[[@REF15],[@REF16]\], Saudi Arabia \[[@REF17]\], Spain \[[@REF18],[@REF19]\], and Norway \[[@REF20]\] while one case series was from Greece \[[@REF21]\]. Koh et al. had reported the first case of S. lugdunensis endocarditis-associated CVA from London, UK in 1996 \[[@REF12]\]. A total of 18 cases from 17 articles were included in the review article. All cases are summarized in Table [1](#TAB1){ref-type="table"} and Table [2](#TAB2){ref-type="table"}.

###### Baseline characteristics and demographic information.

IE: Infective endocarditis; IV: Intravenous; TTE: Trans-thoracic echocardiogram; URI: Upper respiratory tract infection; LV: Left ventricle; PPM: Permanent pacemaker.

  ------------------------------------------------------- ---------------- ------------- ----------- ----------------------- --------------------- ---------------------------------------------- ------------------------------------------ ---------------------------------------------------------- ----------------------
  First author (year) \[Ref. No.\]                        Total patients   Age (Years)   Sex (M/F)   IV Drug abuse history   Previous IE history   Portal of entry                                Location of IE                             Type of valve                                              Vegetation TTE (Y/N)
  Htoo Kyaw (2016) \[[@REF11]\]                           1                63            1/0         Not-mentioned           None                  Unknown                                        Mitral valve                               Native mitral valve                                        Y
  Hossein Schandiz (2015) \[[@REF20]\]                    1                56            1/0         Not-mentioned           None                  Vasectomy                                      Mitral valve                               Native mitral valve                                        N (autopsy finding)
  Manova David (2015) \[[@REF10]\]                        1                36            1/0         Not-mentioned           None                  Vasectomy                                      Mitral valve                               Native mitral valve                                        Y
  Jose Kuzhively (2014) \[[@REF9]\]                       1                61            1/0         Polysubstance abuse     None                  Spinal fracture fixation                       Mitral valve anterior leaflet              Native mitral valve                                        Y
  Wei-Chi Tsai (2013) \[[@REF15]\]                        1                48            1/0         Not-mentioned           None                  Femoral catheterization                        Aortic valve                               Native aortic valve                                        Y
  Federico Pacei (2013) \[[@REF6]\]                       1                77            1/0         Not-mentioned           None                  Mechanical valve replacement for AS and CABG   Mechanical aortic valve                    Mechanical aortic valve                                    Y
  Rosaria Pecoraro (2012) \[[@REF5]\]                     1                18            0/1         Not-mentioned           None                  Not-mentioned                                  Anterior mitral valve leaflets             Native mitral valve                                        Y
  Kalliopi-Stavroula Chatzigeorgiou (2010) \[[@REF21]\]   2                67.5          0/2         Not-mentioned           None                  Not-mentioned                                  LV outflow/PPM lead with Tricuspid valve   Prostatic aortic valve / native tricuspid valve with PPM   Y
  Asmaa Tamdy (2010) \[[@REF14]\]                         1                17            0/1         Not-mentioned           None                  Not-mentioned                                  Mitral valve                               Native mitral valve                                        Y
  Yeun Tarl Fresner Ng Jao (2010) \[[@REF16]\]            1                44            1/0         Not-mentioned           None                  Pneumonia                                      Mitral and aortic valve                    Native mitral and aortic valve                             Y
  Khaled E. Alebrahim (2007) \[[@REF17]\]                 1                13            1/0         Not-mentioned           None                  Not-mentioned                                  Mitral valve                               Native mitral valve                                        Y
  S. Gianella (2006) \[[@REF7]\]                          1                49            0/1         Not-mentioned           None                  Not-mentioned                                  Bicuspid aortic valve                      Native bicuspid aortic valve                               Y
  M Rodríguez-Gascón (2003) \[[@REF18]\]                  1                77            0/1         Not-mentioned           None                  Valvular surgery/URI                           Mitral valve                               Native mitral valve                                        Y
  A. Sánchez (2000) \[[@REF19]\]                          1                71            0/1         Not-mentioned           None                  Not-mentioned                                  Aortic valve                               Native aortic valve                                        Y
  Susan J. Burgert (1999) \[[@REF8]\]                     1                33            1/0         Not-mentioned           None                  Not-mentioned                                  Bicuspid aortic valve                      Native bicuspid aortic valve                               Y
  T. W. Koh (1996) \[[@REF12]\]                           1                52            0/1         Not-mentioned           None                  Not-mentioned                                  Mitral valve                               Native mitral valve                                        Y
  B Walsh and JP Mounsey (1990) \[[@REF13]\]              1                32            1/0         Not-mentioned           None                  Vasectomy                                      Aortic valve                               Native aortic valve                                        N
  ------------------------------------------------------- ---------------- ------------- ----------- ----------------------- --------------------- ---------------------------------------------- ------------------------------------------ ---------------------------------------------------------- ----------------------

###### Summary of infective endocarditis treatment and outcome.

CVA: Cerebrovascular accident; LVOT: Left ventricular outflow tract; PPM: Permanent pacemaker.

  ------------------------------------------------------ ----------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------- ----------------------------- --------------------------------- ---------------------------- -------------------------------------------------------------
  First author (year) \[Ref. No.\]                       Vegetation size on echocardiography                                                             CVA severity                                Medical treatment (Y/N)   Penicillin resistance (Y/N)   Surgical intervention (Y/N)       Required valve replacement   Outcome
  Htoo Kyaw (2016) \[[@REF11]\]                          Vegetation on anterior and posterior mitral valve leaflets                                      Aphasia and right-sided hemiplegia          Y                         N                             Y                                 Y                            Recovered
  Hossein Schandiz (2015)\[[@REF20]\]                    Massive vegetation on mitral valve                                                              Not mentioned: presented as syncope         N                         Y                             N (planned)                       N                            Died before surgery
  Manova David (2015) \[[@REF10]\]                       7 mm on anterior leaflets and 15 mm on posterior leaflet of mitral valve                        Dysarthria and left-sided hemiparesis       Y                         N                             Y                                 Y                            Recovered
  Jose Kuzhively (2014) \[[@REF9]\]                      15.5 x 11.1 mm on the anterior leaflet of the mitral valve                                      Right hemiplegia and facial palsy           Y                         N                             N                                 N                            Recovered
  Wei-Chi Tsai (2013) \[[@REF15]\]                       Aortic valve vegetation with perivalvular abscess                                               Right internuclear ophthalmoplegia          Y                         N                             N (planned)                       N                            Died before surgery
  Federico Pacei (2013) \[[@REF6]\]                      Not mentioned                                                                                   Quadriplegia                                Y                         N                             N                                 N                            Recovered
  Rosaria Pecoraro (2012) \[[@REF5]\]                    10.3 x 16.6 mm on anterior mitral valve leaflet                                                 Right leg weakness                          Y                         N                             Y                                 Y                            Recovered
  Kalliopi-Stavroula Chatzigeorgiou (2010)\[[@REF21]\]   18 x 22 mm at LVOT/7 x 16 mm on PPM leads and small vegetation on tricuspid valve               Dysarthria and facial nerve paresis         Y/Y                       N/N                           Y/N (only removal of PPM wires)   N/N                          Recovered (died 5 years later with calciphylaxis)/Recovered
  Asmaa Tamdy (2010)\[[@REF14]\]                         17 x 5 mm on the anterior mitral valve with small vegetation on both leaflets of mitral valve   Right hemiplegia and aphasia                Y                         N                             N (planned)                       N (planned)                  Died before surgery
  Yeun Tarl Fresner Ng Jao (2010) \[[@REF16]\]           Not mentioned                                                                                   Right hemiparesis                           Y                         N                             Y                                 Y                            Died
  Khaled E. Alebrahim (2007) \[[@REF17]\]                7 x 8 mm on anterior and 3 x 6 mm posterior leaflets of mitral valve                            Right hemiparesis and aphasia               Y                         N                             Y                                 Y                            Recovered
  S. Gianella (2006) \[[@REF7]\]                         12 x 4 mm on the bicuspid aortic valve                                                          Right hemiparesis and aphasia               Y                         N                             Y                                 Y                            Recovered
  M Rodríguez-Gascón (2003) \[[@REF18]\]                 3 x 3 cm vegetation on mitral valve                                                             Left hemiparesis                            Y                         N                             N                                 N                            Recovered
  A. Sánchez (2000) \[[@REF19]\]                         Not mentioned                                                                                   Generalized weakness                        Y                         N                             Y                                 Y                            Recovered
  Susan J. Burgert (1999) \[[@REF8]\]                    5 mm perforation with multiple vegetations on aortic valve                                      Dysarthria, aphasia and right hemiparesis   Y                         N                             Y                                 Y                            Recovered
  T. W. Koh (1996) \[[@REF12]\]                          Vegetation on posterior leaflets of the mitral valve                                            Dysphasia and right facial weakness         Y                         N                             Y                                 Y                            Recovered
  B Walsh and JP Mounsey ( 1990) \[[@REF13]\]            Not mentioned                                                                                   Right-hand weakness                         Y                         N                             Y                                 Y                            Recovered
  ------------------------------------------------------ ----------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------- ----------------------------- --------------------------------- ---------------------------- -------------------------------------------------------------

Demographics

Most of the reported cases were from European countries and only two cases were from China. Four reported cases were from the USA and very limited published data regarding S. lugdunensis endocarditis-induced CVA has been noted in the past literature. Of these 18 cases, 10 were men and eight were women with mean age of 47.9 years (range 13-77 years).

Risk factors, patients' characteristics and clinical spectrum

The risk factors associated with Staphylococcus lugdunensis are intravenous drug abuse, previous history of infective endocarditis, and surgical intervention in the groin area. Among patients with a documented source of infection, four cases (50%) were noted to have either vasectomy or femoral catheterization. No previous history of IE was reported in any of the cases.

Left-sided IE is the most common site involved, accounting for 94.7% of all total cases in which mitral valve, aortic valve, or both amounted to 52.5%, 37%, and 5.2%, respectively (Table [3](#TAB3){ref-type="table"}). Foreign body-related IE comprised three cases including one case with pacemaker-related endocarditis and two cases of prosthetic valve IE. Sixteen individuals (88.88%) were found to have vegetations on echocardiogram with the largest measuring 3 cm x 3 cm in diameter on the mitral valve. The neurological deficit was mostly located in the right side (61%) with facial palsy in 17% and left-sided hemiparesis in 11% (Table [2](#TAB2){ref-type="table"}).

###### Characteristic, location of infected valves, and outcome of Staphylococcus lugdunensis infective endocarditis.

LVOT: Left ventricular outflow tract.

  ---------------------------------------------------------------------- ---------------------------------------------
                                                                         Total cases, N (%)
  Type of infected valve                                                  
  Mitral valve,  aortic valve,  tricuspid valve, pulmonary valve, LVOT   10 (52.5%),  7 (37%),  1 (5.2%),  01 (5.2%)
  Location of vegetation                                                  
  Left sided, right sided                                                17 (94.4%), 1 (5.5%)
  Valve replacement                                                       
  Yes, No                                                                11 (61.1%), 7 (39%)
  Outcome                                                                 
  Recovered, died                                                        14 (78%), 4 (22%)
  ---------------------------------------------------------------------- ---------------------------------------------

Investigation, medical and surgical treatment

Blood culture remains the gold standard to diagnose this type of bacteria and it should be in the differential whenever coagulase-negative Staphylococcus growth is present. Once S. lugdunensis is isolated, early antibiotic therapy and surgical intervention should be considered.

Antibiotic sensitivity testing showed methicillin susceptibility in most of the cases except one case (5.5%) which had penicillin resistance and was consistent with the previous reported literature. In studies by Anguera et al. and Hellbacher et al., S. lugdunensis was susceptible to penicillin with a rate of 84% and 85%, respectively \[[@REF22],[@REF23]\]. Most of the cases were treated with sensitivity-guided medical therapy but 12 cases (66.6%) were eventually required to undergo surgical treatment. This particular finding is relatively higher than other pathogens including S. aureus.

Anguera et al. had reported a four-year study of IE in which surgical intervention was performed in Staphylococcus aureus IE (\~37%), Staphylococcus epidermidis (\~60%), and Staphylococcus lugdunensis (\~70%) \[[@REF22]\]. Another national study done by Ferreiros et al. and Krcmery et al. showed that surgical treatment with valve replacement was done in 26-42% of IE caused by all pathogens \[[@REF24],[@REF25]\]. Despite S. lugdunensis IE-related CVA being mostly methicillin/penicillin sensitive, it is less likely to be eradicated by medical therapy alone and often requires surgical intervention.

Perhaps extrapolating from our experience in treating CVA associated with S. Lugdunensis IE, early surgical treatment was often required to have a better outcome. However, the latest 2015 AHA guideline has failed to mention any specific recommendation for this disease entity \[[@REF26]\]. Thus, clinicians will have to make a decision based on their clinical experiences which could create a heterogeneity in disease management.

Prognosis

Unlike other organisms, S. lugdunensis is characterized by an insidious clinical course resulting in a higher mortality. The mortality rate was 22% (four out of 18 cases) but only one case out of 11 cases that underwent surgical intervention expired compared to those with medical treatment (8.3% vs 37.5%) (Table [3](#TAB3){ref-type="table"}).

Anguera et al. disclosed that the changes in mortality rate before and after 1995 were primarily due to earlier recognition of S. lugdunensis with more aggressive management including surgical intervention \[[@REF22]\]. According to the two studies done in 1993 and 2003, the mortality rate was 16% due to CoNS IE as well as 22.4% with S. aureus IE, which had a reduced mortality rate than our review \[[@REF27],[@REF28]\]. In a 2010 review article done by Liu et al., among 68 patients with S. lugdunensis infective endocarditis, the mortality rate was 38.8% \[[@REF29]\]. Although there are no randomized controlled clinical trials given the disease rarity; based on the above data and past experiences, we can at least extrapolate that early surgical intervention would be a reasonable approach especially in those with CVA related to S. lugdunensis IE.

Conclusions
===========

Compared to other organisms, S. lugdunensis seems to display a higher propensity to cause CVA in our review. In addition, embolic stroke secondary to S. lugdunensis IE appears to have a higher incidence in middle age men than women. Invasive procedures such as catheterization and vasectomy should be performed with proper sterile protocol to help reduce S. lugdunensis bacteremia or endocarditis. Although broad-spectrum antibiotics are typically the first medical treatment option, some patients may require a valve replacement surgery suggesting a higher virulence compared to other CoNS organism. The efficacy of medical therapy alone compared to the possible superiority of early surgical approach needs further investigation. However, it is challenging to conduct future large-scale studies to clarify the exact timeline of the surgical approach as S. lugdunensis endocarditis-related embolic stroke is a rare disease.
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